Close Menu

NEW YORK – Qiagen said on Tuesday that it has signed three agreements to expand its immuno-oncology portfolio for the commercialization of future companion diagnostics, in particular those based on next-generation sequencing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.